Celyad Oncology Completely Shifts To Preclinical Stage, Pulls Plug On Only Human Trial Asset

Celyad Oncology CYAD provides an update on its Celyad 2.0 business strategy, which has been adopted and implemented over the last few months.
The company has compiled a foundational and broad IP estate.
In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in areas including:
- Multiplexing approach of the short hairpin RNA (shRNA) platform.
- Dual CAR development of a next-generation NKG2D-based CAR.
- Development of B7-H6-targeting immunotherapies for several cancers.
Celyad has decided to discontinue the development of its remaining clinical program, CYAD-211 (the allogeneic shRNA-based, anti-BCMA CAR T candidate for relapsed or refractory multiple myeloma.
No safety concerns led to this decision, and all patients previously treated with CYAD-211 will continue to receive their protocol-defined follow-up.
In its Q3 earnings release, the company decided to discontinue the development of CYAD-101 following the previously announced clinical hold resolution.
The company will provide updates on the potential proof-of-concept of the dual CAR and multiplexing research programs and business development in Q2 of 2023.
Price Action: CYAD shares are down 34.72% at $0.6789 during the premarket session on the last check Wednesday.
Photo Via Company